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4-HYDROPEROXYCYCLOPHOSPHAMIDE (4-HC) PURGING OF AUTOLO-
GOUS PERIPHERAL BLOOD PROGENITOR CELLS (PBPC) FOR ACUTE
MYELOID LEUKEMIA (AML)
D.A. Rizzieri, O.M. Colvin, J.J. Vredenburgh, G.D. Long, C.S. Smith,
C. Gilbert, W.P. Petros, N.J. Chao
Duke University, Durham, NC
Patients with advanced AML have a grave prognosis. For those with-
out an allogeneic donor, purging autologous marrow or PBPC could
be an attractive alternative to providing aggressive therapy with less
contaminated products. However, to date there is no randomized
study demonstrating the beneﬁts of purging. We have studied 4-HC,
an active metabolite of cyclophosphamide with potent anti-leukemic
activity. Preclinical work demonstrated that the PBPC are more sen-
sitive to the activity of 4-HC than of bone marrow with 5% reten-
tion of CFU-GMs noted at a purging concentration of 50 ug/mL.
Patients in second remission AML were mobilized with a course
of cytarabine arabinoside 2 g/m2 every 12 hours for 8 total doses and
etoposide 40 mg/kg. G-CSF (10 mcg/kg/d) was initiated 14 days
after chemotherapy. Apheresis was begun when the white blood cell
count reached 3000/uL. The apheresis product was purged with 40
ug/mL of 4-HC. The preparatory regimen consisted of Busulfan 1
mg/kg every 6 hours for 16 doses (adjusted to AUC 900), etoposide
60 mg/kg, and G-CSF 5 ug/kg/d until count recovery.
Results of purging PBPC with 40 ug/mL 4-HC
CD34 CD34 Days to Days to
cells/kg cells/kg ANC platelets
post-purging back-up 500 100,000 Outcome
1 .2  106 Not done 40 75 CR, day 200
2 1.6  107 2.5  107-day 35 * * died, day 50
3 .08  106 .8  105-day 10 45 * relapsed, day 75
In conclusion, these early results demonstrate that PBPC are very
sensitive to 4-HC. Our current strategy results in a poor collection of
CD34 cells and an unacceptably prolonged delay in engraftment.
FANCONI ANEMIA PRESENTING OVER AGE 40—WHEN TO SUSPECT
THE UNEXPECTED IN PATIENTS REQUIRING BONE MARROW TRANS-
PLANTATION
Stephan Thomé, Gerardo Colón-Otero
Mayo Clinic Jacksonville, FL
Fanconi anemia (FA) is an autosomal recessive disease character-
ized by progressive cytopenias and multiple congenital abnormali-
ties. Increased sensitivity to DNA crosslinking agents allows labo-
ratory conﬁrmation and is a hallmark of FA. Mean age at diagnosis
is 8 years. Because of the increased sensitivity to crosslinking
agents, younger patients with bone marrow failure syndromes are
routinely screened for FA before undergoing conditioning for
BMT. In contrast, BMT patients over the age of 20 years are not
routinely screened for FA.
We unexpectedly diagnosed FA in three patients—at age 41, 43
and 48. Hematologic abnormalities included mild cytopenias,
macrocytosis, hypocellular bone marrow, progression to refractory
anemia with excessive blasts, and AML. Examination revealed short
stature, skin pigmentation, biﬁd thumbs, clubfeet, deafness, genital
hypoplasia, and infertility. Family history was positive for anemia
or acute leukemia.
Our data would support a recommendation to screen patients 
for FA up to the age of 50 in the appropiate clinical setting.
EX VIVO EXPANSION OF TRANSPLANTABLE HUMAN HEMATOPOIET-
IC STEM CELLS
Chu-Chih Shih, Mickey Hu, Jun Hu, Jeffrey Medeiros, Stephen J. Forman
City of Hope, Duarte, CA
The development of methods for expanding human hematopoi-
etic stem cells (HSCs) in culture is an important area of research
because of the potential diverse clinical applications. Furthermore,
the establishment of culture systems that facilitate in vitro expan-
sion and maintenance of long-term transplantable HSC activity is a
necessary ﬁrst step toward a cellular and molecular understanding
of the regulatory mechanisms that mediate commitment vs.
self-renewal decisions. A number of recombinant cytokines have
been shown to regulate the kinetics of the primitive HSC growth
both in vitro and in vivo. While expansion has been documented for
hematopoietic cells, it is not yet known whether human HSCs with
long-term engrafting ability are expandable in culture. Using
hematopoietic reconstitution in SCID-hu mice as an in vivo assay
for primitive and transplantable human HSCs, we can demonstrate
an in vitro culture condition in which puriﬁed human HSCs are
expanded 1500-fold, maintain their HSC phenotype, and preserve
their engrafting ability for long-term hematopoietic reconstitution
in SCID-hu mice. Leukemia inhibitory factor (LIF) plays the
determining role in this expansion and maintains the engrafting
potential of transplantable stem cells in this ex vivo culture system.
These data provide evidence suggesting that LIF exerts its role in
expanding transplantable stem cells indirectly by affecting the stro-
mal AC6.21 cells. This study represents the ﬁrst time that HSCs
have been shown to be capable of ex vivo expansion and subsequent
in vivo engraftment.
TANDEM HIGH-DOSE CHEMOTHERAPY (HDC) WITH ESCALATING
PACLITAXEL (P), MELPHALAN (M), CYCLOPHOSPHAMIDE, THIOTEPA,
AND CARBOPLATIN (CTCB) WITH PERIPHERAL BLOOD PROGENITOR
(PBP) SUPPORT IN RESPONDING METASTATIC BREAST CANCER
(MBC)
L.T. Vahdat, C. Balmaceda, K.P. Papadopoulos, T.J. Garrett, D. Savage,
A. Tiersten, T. McGovern, L. Kaufman, K.H. Antman, C.S. Hesdorffer
Herbert Irving Comprehensive Cancer Center, New York, NY
Analysis of prognostic factors associated with durable remissions
include a CR at the end of high-dose therapy. To increase the pro-
portion of patients achieving a CR at the end of therapy, we
designed a tandem HDC program that incorporates a dose-escala-
tion of P as the ﬁrst high-dose cycle. All patients with responding
MBC have a minimum of 3106 CD34 cells/kg leukapheresed
after mobilization with chemotherapy and ﬁlgrastim (G). 
P (400–825 mg/m2) was administered over 24 hours. The second
intensiﬁcation was M at 180 mg/m2 and the third intensiﬁcation was
CTCb (cyclophosphamide 6000 mg/m2, thiotepa 500 mg/m2, car-
boplatin 800 mg/m2). All cycles were supported with PBP and G. 
Thirty-six patients were registered; ﬁve were removed from the
study (inadequate PBP collection, two; progression, two; social rea-
sons, one). Thirty-one patients completed all 3 cycles. Of the 19
patients with measurable disease, six converted to CR, seven con-
verted to a PR* (resolution of soft-tissue/visceral disease with scle-
rosis of bone lesions), and two had a further PR for an overall
response rate of 79%. Some (78%) patients are progression-free at
a median follow-up of 14 months. There were no toxic deaths.
Neurotoxicity was moderate and appears to be unrelated to the
extent of pretreatment with P or site of metastases. Five of 18
patients at a dose level 725 mg/m2 had reversible motor weak-
ness. Phase II is underway at a dose level of 825 mg/m2.
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ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN
THAI PATIENTS
Sanan Visuthisakchai, Viroje Chongkolwatana, Surapol Issaragrisil,
Yaowaluk U-pratya, Maneenop Yimyam, Sukol Visudhiphan
Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok,
Thailand
Peripheral blood stem cell transplantation (PBSCT) has been
used increasingly instead of bone marrow transplantation. From
February 1994 to August 1996, 22 (16 CML, two AML, three
ALL, and one severe aplastic anemia) patients underwent allogene-
ic PBSCT by using unmanipulated filgrastim-mobilized PBSC
from HLA-identical siblings. The median of infused total nucleat-
ed and CD34 cells were 10.8 (1.7–23.4)108 and 0.14
(0.02–3.9)108 cells/kg. The median time of absolute neutrophil
count above 0.5109/L and platelet count above 20109/L were
12 (8–19) and 14 (8–32) days, respectively. Fourteen of these
patients are in disease-free survival. The 2-year disease-free sur-
vival and overall survival were 58.3 and 61.3%, respectively. Two
patients relapsed (one CML, one ALL) at day 334 and 351. Only
three patients developed grade I acute graft-vs.-host disease
(GVHD). No acute GVHD of grade II or more was observed.
Twelve of 17 patients (70.6%) who survived beyond day 100 devel-
oped chronic GVHD. We conclude that allogeneic PBSCT can be
successfully accomplished in Thai patients with low incidence of
acute GVHD, however the incidence of chronic GVHD was high
in this group of patients.
ABSENCE OF PERIPHERAL BLASTS AND YOUNGER DONORS IMPROVE
OUTCOME FOLLOWING PARTIALLY MISMATCHED RELATED DONOR
BONE MARROW TRANSPLANTATION IN PEDIATRIC ACUTE LEUKEMIA
K. Godder, S.A. Abhyankar, K.Y. Chiang, N.P. Christiansen, L.J. Hazlett,
R.S. Parrish, K. Bridges, K. Goon-Johnson, P.J. Henslee-Downey
University of South Carolina and Richland Memorial Hospital, Columbia, SC
For some pediatric patients with acute leukemia, allogeneic bone mar-
row transplant (BMT) is the best hope for cure. Without a matched sib-
ling, immediate access to transplant is feasible with the use of a partially
mismatched related donor (PMRD). In a retrospective analysis of 67
such patients, we sought to determine which pretransplant factors might
predict outcome. At the time of BMT, 23/43 (53%) patients with ALL
and 16/24 (67%) patients with AML were in relapse, 2/3 of whom had
peripheral blasts. Donors (median age 30) included 40 parents, 24 sib-
lings, and three cousins. Disparity of 2–3 major HLA antigen mismatch
(AgMM) was detected in 2/3 donor-recipient pairs. Conditioning thera-
py was followed by partial T-cell depletion using T10B9 (n36) or
OKT3 (n31), combined with post-BMT immunosuppression, as previ-
ously published. The estimated probability (EP) of engraftment was 0.96
(median 17 days) and was not affected by donor AgMM (p  0.732). The
EP of grades II–IV GvHD was 0.24 and was adversely affected by donor
age (p  0.022), but not by recipient AgMM (p  0.796). The EP of
relapse at 4 years was similar for ALL and AML (0.54 and 0.65, respec-
tively). Of interest, for patients in relapse at BMT, absence of peripheral
blasts was associated with a lower relapse rate (0.39 vs. 0.86, p  0.053),
similar to patients in remission (0.44). Donor age 30 years was also
associated with reduced relapse. EP for DFS was 0.28 at 4 years, similar
for ALL and AML, but improved to 0.45 with donors 30 years (p 
0.011) and to 0.61 in the absence of peripheral blasts (p  0.008). Since
multiple PMRDs are usually available, results in our center using effec-
tive transplant techniques indicate that donor choice should be inﬂu-
enced by age and less by degree of disparity. Furthermore, outcome in
relapse patients appears to be enhanced when BMT is performed in the
absence of peripheral blasts.
TOTALLY OUTPATIENT AUTOLOGOUS PERIPHERAL BLOOD STEM
CELL TRANSPLANTS (APBSCT) CAN BE PERFORMED SAFELY WITH A
LOW INCIDENCE OF INFECTIONS
D. Maharaj, J. Gouvea, A. Greenberg, S. Carpenter, S. Bell, P. Knisely,
K. McCoy, G.J. O’Neill
Bone Marrow/Stem Cell Transplant Institute of Florida, Ft. Lauderdale,
FL
Improvements in supportive care, reduction in transplant toxicity, and
increasing pressure to reduce costs are shifting APBSCTs to an outpatient set-
ting. The majority of centers performing outpatient transplants still have an
inpatient component. However, there is limited data on infectious outcomes of
patients undergoing APBSCT in a totally outpatient setting. We have
prospectively analyzed the incidence of infectious complications in 45 patients
(median age 50, range 23–66) with chemosensitive malignancies (breast cancer
25, other solid tumors 7, Hodgkin’s disease and non-Hodgkin’s lymphoma 7,
AML/CML 3, multiple myeloma 3) undergoing APBSCT in a totally outpa-
tient setting. Between January 1995 and December 1997, 40 patients received
myeloablative chemotherapy consisting of BUCY (AML/CML); BEAM
(HD/NHL); CTCb (breast cancer) and ICE (ovarian/germ cell tumor) fol-
lowed by s.c. G-CSF. All patients received prophylactic ciproﬂoxacin (500 p.o.
BID), itraconazole (200 mg p.o. daily), and acyclovir (200 mg p.o. TID) after
mobilization chemotherapy (MC) and ceftazidime (2 g BID), vancomycin (1 g
BID), ﬂuconazole (200 mg i.v. daily), and acyclovir (200 mg p.o. BID) follow-
ing high-dose chemotherapy (HDC). Median day to neutrophil recovery
(ANC 500) was 15 (range 12–40) and 9 (range 8–15) after MC and HDC,
respectively. Infectious outcomes are indicated in the table.
MC (n=45) HDC/APBSCT (n=40)
Any infection or fever 14 (31%) 11 (27.5%)
Isolated febrile episode 6 (13.5%) 11 (27.5%)
Septicaemia 2 (4.5%) 0
Pneumonia 0 0
Catheter-related infection 5 (11%) 0
Invasive fungal infection 0 0
Other infection 1 (2%) 0
The treatment related mortality is 0%. One patient required hospitalization
for prolonged fever after MC and none were hospitalized following HDC.
Totally outpatient transplants can be safely performed with a low incidence of
infectious complications.
CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTA-
TION (ABMT)
B.B. Weinberger, S. Lerchie, K. Blanchard, M.A. Dayton, W. Goeckeler
LSU Medical Center, Shreveport, LA; Cytogen, Princeton, NJ
Relapse is a major reason for treatment failure. Escalation within
the present regimens or expansion with additional agents is difﬁcult
due to toxicity. Sm153 is a radiopharmaceutical with a marked avidity
for bone. Its only known toxicity is myelosuppression. We have
begun a phase I study using Sm153 before the STAMP-V regimen to
increase the dose intensity and better treat bone and marrow disease.
Cohorts of three patients are treated with Sm153 at escalating
doses. Sm153 is administered on day 14 and STAMP-V begins on
day 7. Primed stem cells are infused on day 0.
Seven women with metastatic breast cancer were treated at 2.0
(three patients), 3.0 (three patients), and 4.5 (one patient) mCi/kg.
There was no infusional toxicity; one patient reported mild tran-
sient bone pain. At 3.0 and 4.5 mCi/kg there was a mild decrease in
the WBC and platelet count by day 7. The STAMP-V
chemotherapy was well tolerated. Bone marrow recovery was
prompt. Follow-up has been too short to assess efﬁcacy.
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DISTINCT PATTERNS OF PCR RESULTS PREDICT RISK OF CYTOGE-
NETIC RELAPSE IN PATIENTS WITH CML AFTER ALLOGENEIC BONE
MARROW TRANSPLANT
E. Alyea, A. Chillemi, D. Neuberg, C. Canning, R. Soiffer, J. Ritz
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Donor lymphocyte infusions (DLI) have emerged as an effective treatment
for patients with CML who have relapsed after allogeneic BMT, and is being
used increasingly to treat patients at the time of cytogenetic relapse. The
value and timing of DLI before cytogenetic relapse is unknown. Strategies
using PCR to detect residual bcr-abl cells may be able to identify patients at
high risk of subsequent cytogenetic relapse who may be considered for early
intervention (DLI) or who should be followed closely without treatment. We
have examined PCR results in 72 patients and assessed the incidence of subse-
quent cytogenetic relapse. RT-PCR was performed using nested primers on
samples of bone marrow or peripheral blood obtained while patients were in
complete cytogenetic remission. Four aliquots were analyzed on each sample.
A sample was considered positive if any of the four assays were noted to be
positive. All patients had received CD6 T-cell–depleted marrow as the sole
method of GVHD prophylaxis. Overall, 339 samples were analyzed. The
median number of samples per patient was 4 (range 1–17). Two hundred
three samples were PCR and 136 samples were PCR. In the ﬁrst year after
BMT, 31 patients had at least 1 PCR result, 52 had at least 1 PCR result.
Thirty-five patients had all PCR results and 14 patients had all PCR
results. The predictive value of PCR results obtained in the ﬁrst year after
BMT were analyzed. The estimated risk of cytogenetic relapse at 12 and 24
months after BMT was 8 and 25% for patients with at least 1 PCR result
during the ﬁrst year after BMT compared with 50 and 81% for patients with
no PCR results in the ﬁrst year (log-rank p  0.0001). If patients had at least
1 PCR result at any time during the ﬁrst year post-BMT, the risk of cytoge-
netic relapse was 41% at 12 months and 68% at 24 months compared with
0% and 9% for patients with no PCR results during the ﬁrst year (log-rank p
 0.001). Therefore, the ﬁnding of a single PCR result at any time in the
ﬁrst year after allogeneic BMT is associated with a low incidence of subse-
quent cytogenetic relapse. Patients with all PCR results in the ﬁrst year post-
BMT are at high risk of subsequent cytogenetic relapse and should be consid-
ered for DLI or other therapeutic approaches while in a minimal disease state.
CD6 T-CELL DEPLETION AS THE SOLE METHOD OF GVHD PROPHYLAXIS
IN ADULTS UNDERGOING ALLOGENEIC BMT FROM UNRELATED DONORS 
R. Soiffer, E.P. Alyea, P. Mauch, C. Kuhlman, F. Nazir, J. Antin, J. Ritz
Department of Adult Oncology, Dana-Farber Cancer Institute, Brigham
and Women’s Hospital, Boston, MA
Bone marrow transplantation (BMT) using HLA-matched unrelated donors
is associated with signiﬁcant morbidity and mortality due in part to the high
incidence of graft-vs.-host disease (GVHD) despite aggressive chemoprophylaxis.
T-cell depletion of unrelated donor marrow can decrease the frequency of
GVHD, but has been associated with other complications such as graft failure
and post-BMT lymphoproliferative disorders (PTLPD). Based on the low inci-
dence of graft failure in recipients of CD6-depleted related marrow, we con-
ducted a trial of CD6 depletion in 23 adult patients (15 male, 7 female; ages
20–55 years, median 46 years) undergoing BMT from unrelated donors. Diag-
noses included CML (7), AML (5), MDS (4), ALL (4), NHL (2), and myeloma
(1). Donors were serologically matched at HLA-A and -B loci and matched by
molecular techniques at HLA-DR	1. Four patients were disparate at HLA-DQ
and 2 at HLA-C. Myeloablation consisted of cyclophosphamide (60 mg/kg  2)
and total-body irradiation (1400 cGy). To facilitate engraftment, patients also
received 750 cGy total lymphoid irradiation in the week before admission. CD6
T-cell depletion of donor marrow was the sole form of GVHD prophylaxis. No
additional immune suppressive medications were administered. Patients
received a median of 5.5107 nucleated bone marrow cells/kg after ex vivo treat-
ment with three cycles of T12 (anti-CD6) monoclonal antibody and comple-
ment. Anti-TI2 is an IgM murine monoclonal antibody that reacts only with
mature T cells. G-CSF was administered daily from day 1 to engraftment. An
absolute neutrophil count (ANC) of 500106/L was achieved at a median of
14 days (range 1–22) post-BMT. There were no cases of early or late graft fail-
ure. Grades II–IV acute GVHD occurred in 11 patients (48%); only 2 patients
(9%) developed grade III–IV GVHD. There have been no cases of PTLPD.
There have been 2 relapses in patients with advanced ALL. Day 100
non-relapse mortality is 10%. Some (74%) patients are alive and free of disease
with a median follow-up of 164 (21–735) days . Our data suggest that CD6
depletion of unrelated donor marrow does not impede engraftment and effec-
tively reduces the incidence of grade III–IV acute GVHD in adult patients who
receive HLA-matched unrelated marrow grafts. CD6 depletion of donor mar-
row should be compared with chemoprophylaxis in the prevention of GVHD
for patients undergoing unrelated BMT.
